Managing tyrosine kinase inhibitors side effects in thyroid cancer
| Autor: | Ewa Paliczka-Cieslik, Barbara Jarzab, Jolanta Krajewska |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Sorafenib
Oncology medicine.medical_specialty Cabozantinib Side effect medicine.drug_class Endocrinology Diabetes and Metabolism 030209 endocrinology & metabolism Vandetanib Tyrosine-kinase inhibitor 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Internal medicine Medicine Thyroid cancer business.industry Medullary thyroid cancer medicine.disease respiratory tract diseases Endocrinology chemistry 030220 oncology & carcinogenesis business Lenvatinib medicine.drug |
| Zdroj: | Expert Review of Endocrinology & Metabolism. 12:117-127 |
| ISSN: | 1744-8417 1744-6651 |
| Popis: | Tyrosine kinase inhibitors (TKIs) are a new group of drugs that show the activity against receptors of different growth factors leading to the inhibition of tumor cells growth and proliferation. To date, four different TKIs have been approved for RAI-refractory DTC or MTC: sorafenib, lenvatinib, vandetanib and cabozantinib.This review focuses on treatment toxicity related to above-mentioned TKIs administration in thyroid carcinoma.TKIs cause a variety of side effects in nearly all treated patients, among them: hypertension, gastrointestinal disturbances (diarrhea, abdominal pain, nausea, vomiting), skin reactions (rashes, acne, hand-foot syndrome), fatigue and weight loss. Most of side effects are mild and moderate and manageable by dose adjustment (dose interruptions and dose reductions) and concomitant therapy. However, some complications although rare may be life-threatening or even fatal. Conclusion: TKIs shows an acceptable toxicity profile in patients with advanced and progressive RAI refractory DTC and MTC but only in experienced hands familiar with TKIs, particularly with diagnostics and management of treatment-related complications and also with thyroid carcinoma, what is essential to safely care for the patients and keep them on kinase inhibitor therapy as long as the treatment is beneficial without an unfavorable impact on their quality of life. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|